GlassScriptPhysician profile
Molly E London
NPI 1093843492
$2,299.19
in general payments reported to CMS, 2019-2025
19 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.32 · 2023: $1,059 · 2024: $95.15 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168 · Travel and Lodging: $916 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.47 |
| Travel and Lodging | $916.40 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,058.84 | 2023 | Iovera, Zilretta |
| Stryker Corporation | $244.61 | 2024-2025 | Mako |
| Abbvie INC. | $151.03 | 2025 | |
| Exelixis INC. | $121.95 | 2025 | Cabometyx |
| Janssen Scientific Affairs, LLC | $109.81 | 2025 | Carvykti, Darzalex, Talvey |
| Janssen Biotech, INC. | $95.56 | 2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $92.23 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $66.69 | 2025 | |
| Genmab U.S., INC. | $62.42 | 2025 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $56.27 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $53.73 | 2025 | Ninlaro, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $37.19 | 2021-2025 | Opdivo |
| Progenics Pharmaceuticals, INC. | $28.27 | 2025 | |
| Sumitomo Pharma America, INC. | $23.47 | 2025 | Orgovyx |
| Genzyme Corporation | $22.59 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.49 | 2025 | Verzenio |
| Depuy Synthes Sales INC. | $19.20 | 2024 | Orthovisc, Monovisc |
| Genentech USA, INC. | $16.55 | 2025 | Polivy |
| Pfizer INC. | $16.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly London listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.